Advertisement

Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy

  • Berit Dalsgaard Nielsen
  • Lars Christian Gormsen
  • Ib Tønder Hansen
  • Kresten Krarup Keller
  • Philip Therkildsen
  • Ellen-Margrethe Hauge
Original Article

Abstract

Purpose

To evaluate the in-treatment diagnostic accuracy of FDG PET/CT in large-vessel giant cell arteritis (LV-GCA) by serial scans before and after a short course of high-dose glucocorticoid treatment.

Methods

Twenty-four glucocorticoid-naïve patients with new-onset PET/CT verified LV-GCA (pre-treatment baseline PET) were prospectively included. Excluded were patients with a previous history of GCA or polymyalgia rheumatica, LV-GCA-mimicking conditions and patients on immunosuppressive therapy. All patients were treated with 60 mg of oral prednisolone daily and assigned for in-treatment FDG PET/CT after either 3 (PET3) or 10 days (PET10). Two experienced nuclear medicine physicians, blinded to patients’ clinical data, reviewed the FDG PET/CT images. A visual semi-quantitative approach was used. Segmental and homogenous FDG uptake in the wall of the aorta and/or supra-aortic branches with higher uptake intensity than liver was considered consistent with vasculitis. Inter-reader reliability was evaluated.

Results

Although glucocorticoid treatment attenuated FDG uptake in large vessels, LV-GCA was accurately diagnosed in 10/10 patients after 3 days of treatment, but only in 5/14 patients after 10 days of treatment (p < 0.001). Interrater reliability was substantial (agreement 87%, Cohen’s weighted kappa 0.70). No correlation between CRP and FDG uptake was found.

Conclusions

Within 3 days of high-dose glucocorticoid treatment, FDG PET/CT can diagnose LV-GCA with high sensitivity. This window of opportunity ensures that prompt glucocorticoid treatment can be initiated to avoid debilitating GCA complications with a limited effect on diagnostic accuracy. After 10 days of treatment, FDG PET/CT sensitivity decreases significantly.

Keywords

Giant cell arteritis Large-vessel vasculitis Diagnosis Glucocorticoids 18F-FDG PET/CT 

Notes

Acknowledgements

This work was funded by The Danish Rheumatism Association, Aarhus University, Aarhus University Hospital, Brødrene Hartmann Fond, A.P. Moeller Foundation, Aase & Ejnar Danielsen Foundation. We would like to thank Stine Kramer, MD, Nuclear Medicine and PET Centre, Aarhus University Hospital for scoring of in-treatment PET scans for reliability test; Aparna Udupi, statistician, Faculty of Health, Aarhus University for statistical advice; Morten Pilegaard, Associate Professor, Department of Business Communication, Aarhus University; Partner, Termshare A/S, Denmark and Anne-Birgitte Blavnsfeldt, MD, Department of Rheumatology, Aarhus University Hospital for editing the manuscript.

Disclaimers

The views expressed in the submitted article are the authors’ own and not an official position of the institution or funder.

Funding

This study was funded by The Danish Rheumatism Association, Aarhus University, Aarhus University Hospital, Brødrene Hartmann Foundation, A.P. Moeller Foundation, Aase & Ejnar Danielsen Foundation.

Compliance with ethical standards

Ethical approval

All procedures performed in the study were in accordance with the ethical standards of the National Committee on Health Research Ethics and with the 1964 Helsinki Declaration and its later amendments.

The Central Denmark Region Committees on Health Research Ethics (reference number 1–10–72-60-1) and The Danish Data Protection Agency (reference number 1–16–02-380-1) approved the study.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Conflicts of interests

Ellen-Margrethe Hauge has received fees for speaking from MSD, AbbVie, UCB and Sobi; and received research funding to Aarhus University Hospital from Roche and Novartis.

Supplementary material

259_2018_4021_MOESM1_ESM.pdf (69 kb)
ESM 1 (PDF 68 kb)
259_2018_4021_MOESM2_ESM.pdf (434 kb)
ESM 2 (PDF 433 kb)

References

  1. 1.
    Ashton-Key MR, Gallagher PJ. False-negative temporal artery biopsy. Am J Surg Pathol. 1992;16:634.CrossRefPubMedGoogle Scholar
  2. 2.
    Luqmani R, Lee E, Singh S, Gillett M, Schmidt WA, Bradburn M, et al. The role of ultrasound compared to biopsy of temporal arteries in the diagnosis and treatment of giant cell arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technol Assess (Rockv). 2016;20:1–270.CrossRefGoogle Scholar
  3. 3.
    Schmidt WA, Seifert A, Gromnica-ihle E, Krause A, Natusch A. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology. 2008;47:96–101.CrossRefPubMedGoogle Scholar
  4. 4.
    Muratore F, Kermani TA, Crowson CS, Green AB, Salvarani C, Matteson EL, et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford). 2015;54:463–70.CrossRefGoogle Scholar
  5. 5.
    Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999;42:311–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Fuchs M, Briel M, Daikeler T, Walker UA, Rasch H, Berg S, et al. The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. Eur J Nucl Med Mol Imaging. 2012;39:344–53.CrossRefPubMedGoogle Scholar
  7. 7.e
    Tuckwell K, Collinson N, Dimonaco S, Klearman M, Blockmans D, Brouwer E, et al. Newly diagnosed vs. relapsing giant cell arteritis: baseline data from the GiACTA trial. Semin Arthritis Rheum. 2017;46:657–64.CrossRefPubMedGoogle Scholar
  8. 8.
    Stellingwerff MD, Brouwer E, Lensen K-JDF, Rutgers A, Arends S, van der Geest KSM, et al. Different scoring methods of FDG PET/CT in Giant cell arteritis. Medicine (Baltimore). 2015;94:e1542.CrossRefGoogle Scholar
  9. 9.
    Walter MA, Melzer RA, Schindler C, Müller-Brand J, Tyndall A, Nitzsche EU. The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging. 2005;32:674–81.CrossRefPubMedGoogle Scholar
  10. 10.
    Prieto-González S, Depetris M, García-Martínez A, Espígol-Frigolé G, Tavera-Bahillo I, Corbera-Bellata M, et al. Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case–control study. Ann Rheum Dis. 2014;73:1388–92.CrossRefPubMedGoogle Scholar
  11. 11.
    Henes JC, Müller M, Krieger J, Balletshofer B, Pfannenberg AC, Kanz L, et al. [18F] FDG-PET/CT as a new and sensitive imaging method for the diagnosis of large vessel vasculitis. Clin Exp Rheumatol. 2008;26:S47–52.PubMedGoogle Scholar
  12. 12.
    Lensen KDF, Comans EFI, Voskuyl AE, Van Der Laken CJ, Brouwer E, Zwijnenburg AT, et al. Large-vessel vasculitis: Interobserver agreement and diagnostic accuracy of 18F-FDG-PET/CT. Biomed Res Int 2015. Article ID 914692.Google Scholar
  13. 13.
    Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology. 2010;49:1594–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.CrossRefPubMedGoogle Scholar
  15. 15.
    Mehta NN, Torigian DA, Gelfand JM, Saboury B, Alavi A. Quantification of atherosclerotic plaque activity and vascular inflammation using [18-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). J Vis Exp 2012:e3777.Google Scholar
  16. 16.
    Soussan M, Nicolas P, Schramm C, Katsahian S, Pop G, Fain O, et al. Management of Large-Vessel Vasculitis with FDG-PET. Medicine (Baltimore). 2015;94:e622.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Besson FL, Parienti J-J, Bienvenu B, Prior JO, Costo S, Bouvard G, et al. Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38:1764–72.CrossRefPubMedGoogle Scholar
  18. 18.
    Treglia G, Mattoli MV, Leccisotti L, Ferraccioli G, Giordano A. Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review. Clin Rheumatol. 2011;30:1265–75.CrossRefPubMedGoogle Scholar
  19. 19.
    Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68:318–23.CrossRefPubMedGoogle Scholar
  20. 20.
    Clifford AH, Murphy EM, Burrell SC, Bligh MP, MacDougall RF, Heathcote JG, et al. Positron emission tomography/computerized tomography in newly diagnosed patients with Giant cell arteritis who are taking glucocorticoids. J Rheumatol. 2017;44:1859–66.CrossRefPubMedGoogle Scholar
  21. 21.
    Meller J, Strutz F, Siefker U, Scheel A, Sahlmann CO, Lehmann K, et al. Early diagnosis and follow-up of aortitis with [18F]FDG PET and MRI. Eur J Nucl Med Mol Imaging. 2003;30:730–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Moosig F, Czech N, Mehl C, Henze E, Zeuner R, Kneba M, et al. Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: a quantitative PET study. Ann Rheum Dis. 2004;63:870–3.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Blockmans D, de Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum. 2006;55:131–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Tarzi RM, Mason JC, Pusey CD. Issues in trial design for ANCA-associated and large-vessel vasculitis. Nat Rev Rheumatol. 2014;10:502–10.CrossRefPubMedGoogle Scholar
  25. 25.
    Seeliger B, Sznajd J, Robson JC, Judge A, Craven A, Grayson PC, et al. Are the 1990 American College of Rheumatology vasculitis classification criteria still valid? Rheumatology. 2017;56:1154–61.CrossRefPubMedGoogle Scholar
  26. 26.
    Unizony SH, Dasgupta B, Fisheleva E, Rowell L, Schett G, Spiera R, et al. Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol 2013;2013.Google Scholar
  27. 27.
    Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al. A randomized, double-blind trial of Abatacept (CTLA-4Ig) for the treatment of Giant cell arteritis. Arthritis Rheumatol. 2017;69:837–45.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    de Boysson H, Lambert M, Liozon E, Boutemy J, Maigné G, Ollivier Y, et al. Giant-cell arteritis without cranial manifestations. Medicine (Baltimore). 2016;95:e3818.CrossRefGoogle Scholar
  29. 29.
    Förster S, Tato F, Weiss M, Czihal M, Rominger A, Bartenstein P, et al. Patterns of extracranial involvement in newly diagnosed giant cell arteritis assessed by physical examination, colour coded duplex sonography and FDG-PET. Vasa. 2011;40:219–27.CrossRefPubMedGoogle Scholar
  30. 30.
    Lariviere D, Benali K, Coustet B, Pasi N, Hyafil F, Klein I, et al. Positron emission tomography and computed tomography angiography for the diagnosis of giant cell arteritis. Medicine (Baltimore). 2016;95:e4146.CrossRefGoogle Scholar
  31. 31.
    Prieto-González S, Arguis P, García-Martínez A, Espígol-Frigolé G, Tavera-Bahillo I, Butjosa M, et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis. 2012;71:1170–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Lehmann P, Buchtala S, Achajew N, Haerle P, Ehrenstein B, Lighvani H, et al. 18F-FDG PET as a diagnostic procedure in large vessel vasculitis-a controlled, blinded re-examination of routine PET scans. Clin Rheumatol. 2011;30:37–42.CrossRefPubMedGoogle Scholar
  33. 33.
    Martínez-Rodríguez I, Martínez-Amador N, Banzo I, Quirce R, Jiménez-Bonilla J, De Arcocha-Torres M, et al. Assessment of aortitis by semiquantitative analysis of 180-min 18F-FDG PET/CT acquisition images. Eur J Nucl Med Mol Imaging. 2014;41:2319–24.CrossRefPubMedGoogle Scholar
  34. 34.
    Besson FL, De Boysson H, Parienti JJ, Bouvard G, Bienvenu B, Agostini D. Towards an optimal semiquantitative approach in giant cell arteritis: an 18F-FDG PET/CT case-control study. Eur J Nucl Med Mol Imaging. 2014;41:155–66.CrossRefPubMedGoogle Scholar
  35. 35.
    Hautzel H, Sander O, Heinzel A, Schneider M, Müller H-W. Assessment of large-vessel involvement in giant cell arteritis with 18F-FDG PET: introducing an ROC-analysis-based cutoff ratio. J Nucl Med. 2008;49:1107–13.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of RheumatologyAarhus University HospitalÅrhus CDenmark
  2. 2.Department of Clinical MedicineAarhus UniversityAarhusDenmark
  3. 3.Department of Nuclear Medicine and PET CentreAarhus University HospitalAarhusDenmark

Personalised recommendations